{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-031966","form_type":"8-K","ticker":"GNPX","cik":"0001595248","company_name":"Genprex, Inc.","filed_at":"2024-10-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.913211+00:00","generated_at":"2026-05-30T10:30:42.912107+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Genprex partners with U Michigan to study REQORSA plus ALK-inhibitors in ALK+ lung cancer","bullets":["Entered Sponsored Research Agreement with Univ. of Michigan Rogel Cancer Center for TUSC2/REQORSA combo with ALK-inhibitors.","Collaboration with ALK Positive nonprofit; both share cost of the SRA.","Preclinical data (AACR Apr 2024): REQORSA induced apoptosis in alectinib-resistant EML4-ALK+ NSCLC lines.","TUSC2 overexpression via REQORSA decreased cell growth and proliferation through apoptotic pathway activation."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-031966","json":"https://secwatch.observer/filing/0001437749-24-031966.json","markdown":"https://secwatch.observer/filing/0001437749-24-031966.md","text":"https://secwatch.observer/filing/0001437749-24-031966.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1595248/000143774924031966/0001437749-24-031966-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1595248/000143774924031966/gnpx20241002_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T10:30:42.912107+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}